Literature DB >> 16882303

Treatment of acute post-surgical infection of joint arthroplasty.

A Soriano1, S García, G Bori, M Almela, X Gallart, F Macule, J Sierra, J A Martínez, S Suso, J Mensa.   

Abstract

The best antibiotic regimen for acute prosthetic joint infection, treated without removal of the implant, has not been well-defined. This study describes the use of a protocol based on oral rifampicin combinations to treat 47 cases that were followed prospectively for a 2-year period. The regimen used most commonly was levofloxacin 500 mg/24 h plus rifampicin 600 mg/24 h for a mean duration of 2.7 +/- 1 months. The cure rate was 76.9%, and the only independent risk-factor associated with treatment failure was infection caused by methicillin-resistant Staphylococcus aureus or Enterococcus spp. (OR 17.6, p 0.003). Overall, the results suggested that use of oral antibiotics, including rifampicin, for 2-3 months was a good treatment option.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16882303     DOI: 10.1111/j.1469-0691.2006.01463.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  35 in total

1.  Antibiotic resistance in orthopaedic surgery: acute knee prosthetic joint infections due to extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae.

Authors:  J C Martínez-Pastor; F Vilchez; C Pitart; J M Sierra; A Soriano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-15       Impact factor: 3.267

Review 2.  Infection in total hip replacement: meta-analysis.

Authors:  Surendra Senthi; Jacob T Munro; Rocco P Pitto
Journal:  Int Orthop       Date:  2010-11-18       Impact factor: 3.075

3.  Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention.

Authors:  O C El Helou; E F Berbari; B D Lahr; J E Eckel-Passow; R R Razonable; I G Sia; A Virk; R C Walker; J M Steckelberg; W R Wilson; A D Hanssen; D R Osmon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-27       Impact factor: 3.267

4.  Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection.

Authors:  O Murillo; M E Pachón; G Euba; R Verdaguer; F Tubau; C Cabellos; J Cabo; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

Review 5.  [Periprosthetic infections of the hip joint : Clinical approach].

Authors:  H M L Mühlhofer; H Gollwitzer; F Lenze; S Feihl; F Pohlig; R von Eisenhart-Rothe; J Schauwecker
Journal:  Orthopade       Date:  2015-05       Impact factor: 1.087

6.  Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection.

Authors:  Daniela Baldoni; Manuel Haschke; Zarko Rajacic; Werner Zimmerli; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

7.  High activity of Fosfomycin and Rifampin against methicillin-resistant staphylococcus aureus biofilm in vitro and in an experimental foreign-body infection model.

Authors:  Raluca Mihailescu; Ulrika Furustrand Tafin; Stéphane Corvec; Alessandra Oliva; Bertrand Betrisey; Oliver Borens; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

8.  A superficial swab culture is useful for microbiologic diagnosis in acute prosthetic joint infections.

Authors:  Jordi Cuñé; Alex Soriano; Juan C Martínez; Sebastián García; Josep Mensa
Journal:  Clin Orthop Relat Res       Date:  2008-10-11       Impact factor: 4.176

9.  Results after late polymicrobial, gram-negative, and methicillin-resistant infections in knee arthroplasty.

Authors:  José Cordero-Ampuero; Jaime Esteban; Eduardo García-Rey
Journal:  Clin Orthop Relat Res       Date:  2010-05       Impact factor: 4.176

Review 10.  Role of Rifampin against Staphylococcal Biofilm Infections In Vitro, in Animal Models, and in Orthopedic-Device-Related Infections.

Authors:  Werner Zimmerli; Parham Sendi
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.